Inebilizumab reduces the risk of flares in IgG4-related disease
1. In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased the likelihood...
Rheumatology
Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis
1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients...
Prenatal systemic glucocorticoid exposure may be associated with increased risk of future mental disorder
1. In this cohort study of offspring born to mothers at risk for preterm delivery or diagnosed with an autoimmune...
Heated mittens not found to improve physical hand function in patients with osteoarthritis
1. The use of electrically heated mittens for 6 weeks was not associated with improved physical hand function in patients...
Roles of low muscle strength and sarcopenic obesity on incident symptomatic knee osteoarthritis
1. Low muscle strength, obesity, and sarcopenic obesity were associated with a greater risk of incident symptomatic knee osteoarthritis (OA)...
Semaglutide reduces body weight and pain symptoms in obese patients with knee osteoarthritis
1. In this randomized controlled trial, once-weekly semaglutide led to significant weight loss compared to placebo over 68 weeks in...
Paretic limbs suffer greater loss of bone mineral density following stroke
1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and balance deficits...
![No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/07/Sjogren_syndrome_2-350x250.jpg)
Iscalimab shows dose-dependent improvement among patients with active Sjögren’s disease
1. Isaclimab significantly improved disease activity at 150 mg and 600 mg doses. 2. Adverse events were comparable between cohorts...
